These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36674985)

  • 1. Optimized Antimicrobial Peptide Jelleine-I Derivative Br-J-I Inhibits Fusobacterium Nucleatum to Suppress Colorectal Cancer Progression.
    Jia F; Yu Q; Wang R; Zhao L; Yuan F; Guo H; Shen Y; He F
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium New Houttuyfonate Inhibits Cancer-Promoting
    Jia F; Yu Q; Zhao L; Shen Y; Guo H; He F
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphiphilic polymeric nanodrug integrated with superparamagnetic iron oxide nanoparticles for synergistic antibacterial and antitumor therapy of colorectal cancer.
    Li X; Niu J; Deng L; Yu Y; Zhang L; Chen Q; Zhao J; Wang B; Gao H
    Acta Biomater; 2024 Jan; 173():432-441. PubMed ID: 37984629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2.
    Guo P; Tian Z; Kong X; Yang L; Shan X; Dong B; Ding X; Jing X; Jiang C; Jiang N; Yu Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):202. PubMed ID: 32993749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
    Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
    J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression.
    Kong X; Zhang Y; Xiang L; You Y; Duan Y; Zhao Y; Li S; Wu R; Zhang J; Zhou L; Duan L
    J Exp Clin Cancer Res; 2023 Sep; 42(1):236. PubMed ID: 37684625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism.
    Ou S; Wang H; Tao Y; Luo K; Ye J; Ran S; Guan Z; Wang Y; Hu H; Huang R
    Front Cell Infect Microbiol; 2022; 12():1020583. PubMed ID: 36523635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin.
    Rubinstein MR; Wang X; Liu W; Hao Y; Cai G; Han YW
    Cell Host Microbe; 2013 Aug; 14(2):195-206. PubMed ID: 23954158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085.
    Hui B; Zhou C; Xu Y; Wang R; Dong Y; Zhou Y; Ding J; Zhang X; Xu J; Gu Y
    J Nanobiotechnology; 2024 Feb; 22(1):62. PubMed ID: 38360615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of halogenation on the antimicrobial activity, antibiofilm activity, cytotoxicity and proteolytic stability of the antimicrobial peptide Jelleine-I.
    Jia F; Zhang Y; Wang J; Peng J; Zhao P; Zhang L; Yao H; Ni J; Wang K
    Peptides; 2019 Feb; 112():56-66. PubMed ID: 30500360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
    Yang Y; Weng W; Peng J; Hong L; Yang L; Toiyama Y; Gao R; Liu M; Yin M; Pan C; Li H; Guo B; Zhu Q; Wei Q; Moyer MP; Wang P; Cai S; Goel A; Qin H; Ma Y
    Gastroenterology; 2017 Mar; 152(4):851-866.e24. PubMed ID: 27876571
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hu L; Liu Y; Kong X; Wu R; Peng Q; Zhang Y; Zhou L; Duan L
    Front Immunol; 2021; 12():658681. PubMed ID: 34093546
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Chen S; Su T; Zhang Y; Lee A; He J; Ge Q; Wang L; Si J; Zhuo W; Wang L
    Gut Microbes; 2020 May; 11(3):511-525. PubMed ID: 31910722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.
    Chen Y; Peng Y; Yu J; Chen T; Wu Y; Shi L; Li Q; Wu J; Fu X
    Oncotarget; 2017 May; 8(19):31802-31814. PubMed ID: 28423670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances on the treatment of
    Wang H; Hou X; Liu J; Yang C
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3670-3680. PubMed ID: 37805845
    [No Abstract]   [Full Text] [Related]  

  • 16. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview.
    Hashemi Goradel N; Heidarzadeh S; Jahangiri S; Farhood B; Mortezaee K; Khanlarkhani N; Negahdari B
    J Cell Physiol; 2019 Mar; 234(3):2337-2344. PubMed ID: 30191984
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang Z; Ji G
    Oncol Lett; 2019 Aug; 18(2):975-982. PubMed ID: 31423156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    LaCourse KD; Zepeda-Rivera M; Kempchinsky AG; Baryiames A; Minot SS; Johnston CD; Bullman S
    Cell Rep; 2022 Nov; 41(7):111625. PubMed ID: 36384132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
    Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer.
    Yamamoto S; Kinugasa H; Hirai M; Terasawa H; Yasutomi E; Oka S; Ohmori M; Yamasaki Y; Inokuchi T; Harada K; Hiraoka S; Nouso K; Tanaka T; Teraishi F; Fujiwara T; Okada H
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1869-1876. PubMed ID: 33242360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.